lisdexamfetamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anorexics	4135	608137-32-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lisdexamfetamine lisdexamphetamine lisdexamfetamine dimesylate vyvanse lisdexamfetamine mesilate	A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER. Molecular weight: 263.39 Formula: C15H25N3O CLOGP: 0.81 LIPINSKI: 0 HAC: 4 HDO: 3 TPSA: 81.14 ALOGS: -3.48 ROTB: 8 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lisdexamfetamine
lisdexamphetamine
lisdexamfetamine dimesylate
vyvanse
lisdexamfetamine mesilate

A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

Molecular weight: 263.39
Formula: C15H25N3O
CLOGP: 0.81
LIPINSKI: 0
HAC: 4
HDO: 3
TPSA: 81.14
ALOGS: -3.48
ROTB: 8

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	17 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 23, 2007	FDA	SHIRE DEVELOPMENT
March 26, 2019	PMDA	SHIONOGI & CO., LTD.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product quality issue	814.96	17.86	307	13219	30551	50561047
Disturbance in attention	321.93	17.86	160	13366	31026	50560572
Product physical issue	320.77	17.86	94	13432	4238	50587360
Inappropriate schedule of product administration	188.61	17.86	155	13371	71676	50519922
No adverse event	175.02	17.86	110	13416	33468	50558130
Drug ineffective	153.89	17.86	522	13004	818811	49772787
Wrong technique in product usage process	150.31	17.86	122	13404	55388	50536210
Anxiety	138.89	17.86	202	13324	177404	50414194
Feeling abnormal	122.55	17.86	159	13367	125333	50466265
Therapeutic product effect increased	106.76	17.86	29	13497	987	50590611
Prescribed overdose	105.26	17.86	59	13467	14541	50577057
Irritability	104.49	17.86	75	13451	28351	50563247
Tic	101.58	17.86	29	13497	1188	50590410
Suicidal ideation	94.79	17.86	94	13432	55291	50536307
Therapeutic response unexpected	85.03	17.86	53	13473	15862	50575736
Therapeutic product effect decreased	84.14	17.86	139	13387	135911	50455687
Therapeutic product effect variable	82.18	17.86	24	13502	1066	50590532
Product dose omission issue	82.08	17.86	163	13363	183675	50407923
Incorrect dose administered	77.02	17.86	79	13447	48335	50543263
Product tampering	74.51	17.86	16	13510	194	50591404
Therapeutic response shortened	70.53	17.86	36	13490	7353	50584245
Rhesus incompatibility	68.27	17.86	13	13513	81	50591517
Depression	68.25	17.86	142	13384	165281	50426317
Insomnia	59.55	17.86	139	13387	174726	50416872
Anger	56.18	17.86	36	13490	11297	50580301
Feeling jittery	54.21	17.86	35	13491	11125	50580473
Abnormal behaviour	52.70	17.86	43	13483	19615	50571983
Withdrawal syndrome	52.54	17.86	41	13485	17549	50574049
Somnolence	52.53	17.86	123	13403	154862	50436736
Psychomotor hyperactivity	52.28	17.86	32	13494	9269	50582329
Premature delivery	51.66	17.86	46	13480	23617	50567981
Impulsive behaviour	51.39	17.86	18	13508	1440	50590158
Mood swings	49.42	17.86	38	13488	15916	50575682
Aggression	45.99	17.86	41	13485	21075	50570523
Pre-existing condition improved	43.98	17.86	26	13500	7071	50584527
Acute kidney injury	43.57	17.86	5	13521	228053	50363545
Attention deficit hyperactivity disorder	42.46	17.86	18	13508	2411	50589187
Paranoia	41.94	17.86	29	13497	10319	50581279
Pneumonia	41.42	17.86	25	13501	378376	50213222
Unevaluable event	41.21	17.86	56	13470	46010	50545588
Inability to afford medication	39.45	17.86	15	13511	1515	50590083
Intentional overdose	38.75	17.86	64	13462	62440	50529158
Suspected product quality issue	36.97	17.86	9	13517	196	50591402
Logorrhoea	36.61	17.86	16	13510	2308	50589290
Agitation	36.28	17.86	57	13469	53327	50538271
Acne	34.87	17.86	34	13492	19561	50572037
Amphetamines positive	33.80	17.86	8	13518	154	50591444
Euphoric mood	33.67	17.86	18	13508	4037	50587561
Mood altered	32.27	17.86	27	13499	12746	50578852
Crying	31.87	17.86	33	13493	20383	50571215
Performance status decreased	31.75	17.86	16	13510	3179	50588419
Educational problem	31.49	17.86	9	13517	370	50591228
Heart rate increased	31.42	17.86	66	13460	77184	50514414
Death	30.95	17.86	25	13501	325354	50266244
Joint swelling	30.05	17.86	14	13512	245272	50346326
Serotonin syndrome	30.00	17.86	35	13491	24678	50566920
Stress cardiomyopathy	29.40	17.86	21	13505	7866	50583732
Tremor	29.34	17.86	82	13444	114821	50476777
Amphetamines negative	28.91	17.86	4	13522	0	50591598
Anaemia	28.55	17.86	16	13510	252440	50339158
Off label use	28.34	17.86	220	13306	474206	50117392
Mydriasis	27.96	17.86	23	13503	10604	50580994
Exposure via skin contact	27.25	17.86	7	13519	191	50591407
Mania	25.38	17.86	22	13504	10894	50580704
Drug diversion	25.27	17.86	9	13517	756	50590842
Systemic lupus erythematosus	24.67	17.86	4	13522	140618	50450980
Pyrexia	24.47	17.86	40	13486	380163	50211435
Stress	24.28	17.86	48	13478	53745	50537853
Rabbit syndrome	23.92	17.86	7	13519	313	50591285
Bruxism	23.86	17.86	13	13513	3027	50588571
Suicide attempt	23.16	17.86	46	13480	51686	50539912
Negativism	22.92	17.86	7	13519	363	50591235
Diarrhoea	22.75	17.86	81	13445	588395	50003203
Depressed mood	22.65	17.86	36	13490	33987	50557611
Product availability issue	22.36	17.86	11	13515	2077	50589521
Drug dependence	22.35	17.86	27	13499	19732	50571866
Nervousness	22.31	17.86	32	13494	27619	50563979
Change in sustained attention	21.68	17.86	3	13523	0	50591598
Foetal chromosome abnormality	21.28	17.86	4	13522	23	50591575
Product taste abnormal	21.12	17.86	10	13516	1735	50589863
Memory impairment	20.60	17.86	57	13469	79303	50512295
Rheumatoid arthritis	19.94	17.86	15	13511	202535	50389063
Haemoglobin decreased	19.45	17.86	5	13521	127211	50464387
Dry mouth	19.44	17.86	45	13481	56133	50535465
Arthropathy	19.34	17.86	9	13517	157897	50433701
Dermatillomania	19.01	17.86	5	13521	150	50591448
Palpitations	18.98	17.86	62	13464	94444	50497154
Infusion related reaction	18.79	17.86	11	13515	169546	50422052
Fall	18.21	17.86	39	13487	334893	50256705
Treatment failure	18.21	17.86	7	13519	137630	50453968
Distractibility	18.17	17.86	6	13520	401	50591197
Vision blurred	18.01	17.86	54	13472	78593	50513005

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product quality issue	789.97	28.25	271	10123	15624	29548509
Product physical issue	291.66	28.25	79	10315	2009	29562124
Aggression	271.88	28.25	164	10230	35377	29528756
Disturbance in attention	262.99	28.25	135	10259	21289	29542844
Tic	244.96	28.25	67	10327	1768	29562365
Drug ineffective	229.41	28.25	434	9960	362736	29201397
Therapeutic product effect decreased	222.81	28.25	135	10259	29316	29534817
Psychomotor hyperactivity	219.39	28.25	89	10305	8124	29556009
No adverse event	214.04	28.25	110	10284	17368	29546765
Irritability	192.26	28.25	111	10283	22041	29542092
Suicidal ideation	188.08	28.25	129	10265	34587	29529546
Inappropriate schedule of product administration	178.93	28.25	138	10256	44334	29519799
Therapeutic product effect increased	174.03	28.25	41	10353	579	29563554
Abnormal behaviour	169.68	28.25	104	10290	23023	29541110
Anxiety	152.34	28.25	168	10226	85197	29478936
Insomnia	150.37	28.25	170	10224	88591	29475542
Wrong technique in product usage process	145.19	28.25	106	10288	31322	29532811
Crying	132.68	28.25	55	10339	5296	29558837
Choreoathetosis	130.36	28.25	36	10358	984	29563149
Disturbance in social behaviour	128.78	28.25	40	10354	1662	29562471
Oppositional defiant disorder	112.53	28.25	28	10366	503	29563630
Bruxism	110.49	28.25	35	10359	1552	29562581
Prescribed overdose	110.13	28.25	56	10338	8627	29555506
Decreased eye contact	104.92	28.25	26	10368	459	29563674
Anger	98.22	28.25	56	10338	10834	29553299
Mood altered	93.32	28.25	49	10345	8062	29556071
Homicidal ideation	90.91	28.25	34	10360	2490	29561643
Logorrhoea	90.43	28.25	33	10361	2255	29561878
Incorrect dose administered	90.26	28.25	82	10312	32902	29531231
Educational problem	88.11	28.25	23	10371	504	29563629
Negativism	85.65	28.25	21	10373	354	29563779
Impulsive behaviour	80.44	28.25	29	10365	1914	29562219
Acute kidney injury	80.31	28.25	3	10391	265264	29298869
Decreased appetite	80.18	28.25	165	10229	145177	29418956
Dystonia	79.60	28.25	47	10347	9702	29554431
Pneumonia	78.83	28.25	10	10384	320162	29243971
Product administered to patient of inappropriate age	78.58	28.25	31	10363	2624	29561509
Feeling abnormal	78.25	28.25	96	10298	54349	29509784
Agitation	76.23	28.25	92	10302	51212	29512921
Emotional disorder	75.00	28.25	36	10358	4895	29559238
Affect lability	74.43	28.25	32	10362	3370	29560763
Dyskinesia	73.52	28.25	59	10335	20002	29544131
Therapeutic response shortened	66.92	28.25	33	10361	4758	29559375
Depressed mood	65.92	28.25	51	10343	16397	29547736
Depression	64.75	28.25	111	10283	85036	29479097
Speech disorder	61.45	28.25	57	10337	23459	29540674
Death	61.33	28.25	22	10372	342062	29222071
Therapeutic product effect variable	59.37	28.25	23	10371	1854	29562279
Product tampering	54.30	28.25	10	10384	36	29564097
Nervousness	54.11	28.25	39	10355	11267	29552866
Paranoia	54.08	28.25	37	10357	9840	29554293
Sleep disorder	52.23	28.25	53	10341	24333	29539800
Trichotillomania	49.69	28.25	10	10384	63	29564070
Attention deficit hyperactivity disorder	48.97	28.25	21	10373	2196	29561937
Trismus	47.60	28.25	21	10373	2352	29561781
Coordination abnormal	47.08	28.25	30	10364	7084	29557049
Oculogyric crisis	44.19	28.25	17	10377	1344	29562789
Adverse event	41.75	28.25	38	10356	15253	29548880
Off label use	41.08	28.25	211	10183	300589	29263544
Dermatillomania	40.52	28.25	8	10386	45	29564088
Sepsis	38.80	28.25	3	10391	142679	29421454
Inability to afford medication	38.06	28.25	14	10380	978	29563155
Product dose omission issue	37.02	28.25	95	10299	96288	29467845
Feeling jittery	36.32	28.25	20	10374	3613	29560520
Pyrexia	36.13	28.25	29	10365	287593	29276540
Headache	35.75	28.25	138	10256	173869	29390264
Mania	35.00	28.25	27	10367	8636	29555497
Hyperkinesia	34.84	28.25	15	10379	1584	29562549
Intentional self-injury	34.08	28.25	31	10363	12430	29551703
Product prescribing error	33.01	28.25	36	10358	17940	29546193
Psychotic disorder	32.66	28.25	38	10356	20316	29543817
Breech presentation	32.50	28.25	8	10386	137	29563996
Streptococcal infection	32.39	28.25	20	10374	4468	29559665
Change in sustained attention	31.31	28.25	5	10389	5	29564128
Hunger	30.53	28.25	13	10381	1336	29562797
Suicidal behaviour	30.38	28.25	13	10381	1352	29562781
Neutropenia	30.25	28.25	5	10389	131706	29432427
Thinking abnormal	29.57	28.25	20	10374	5216	29558917
Polydipsia psychogenic	28.89	28.25	7	10387	112	29564021
Renal failure	28.38	28.25	4	10390	118595	29445538

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product quality issue	968.11	18.54	346	17000	29453	64451933
Disturbance in attention	394.24	18.54	201	17145	40873	64440513
Tic	299.49	18.54	80	17266	2539	64478847
Aggression	287.77	18.54	170	17176	46062	64435324
Product physical issue	273.23	18.54	79	17267	3370	64478016
Irritability	236.20	18.54	138	17208	36608	64444778
Psychomotor hyperactivity	219.21	18.54	97	17249	14354	64467032
Suicidal ideation	213.39	18.54	162	17184	66380	64415006
Therapeutic product effect increased	211.96	18.54	53	17293	1287	64480099
Inappropriate schedule of product administration	188.37	18.54	173	17173	92113	64389273
Abnormal behaviour	184.27	18.54	114	17232	33508	64447878
Drug ineffective	179.32	18.54	562	16784	839685	63641701
Anxiety	171.29	18.54	240	17106	202409	64278977
Insomnia	165.26	18.54	233	17113	197603	64283783
Wrong technique in product usage process	165.08	18.54	138	17208	64836	64416550
Feeling abnormal	148.20	18.54	181	17165	133421	64347965
Therapeutic product effect decreased	137.29	18.54	162	17184	115189	64366197
Crying	125.21	18.54	74	17272	20016	64461370
Anger	125.15	18.54	68	17278	15673	64465713
No adverse event	124.78	18.54	84	17262	28477	64452909
Choreoathetosis	122.89	18.54	35	17311	1412	64479974
Logorrhoea	119.79	18.54	44	17302	4015	64477371
Oppositional defiant disorder	111.77	18.54	26	17320	460	64480926
Homicidal ideation	106.18	18.54	38	17308	3219	64478167
Bruxism	105.90	18.54	39	17307	3585	64477801
Agitation	104.91	18.54	124	17222	88243	64393143
Therapeutic product effect variable	101.22	18.54	31	17315	1613	64479773
Educational problem	100.29	18.54	23	17323	381	64481005
Decreased eye contact	100.05	18.54	26	17320	739	64480647
Mood altered	94.73	18.54	57	17289	15922	64465464
Impulsive behaviour	94.15	18.54	33	17313	2630	64478756
Acute kidney injury	91.47	18.54	8	17338	449232	64032154
Product dose omission issue	91.36	18.54	177	17169	194570	64286816
Attention deficit hyperactivity disorder	89.10	18.54	32	17314	2738	64478648
Dyskinesia	88.45	18.54	78	17268	39310	64442076
Pneumonia	86.67	18.54	22	17324	559554	63921832
Disturbance in social behaviour	85.47	18.54	34	17312	3853	64477533
Prescribed overdose	82.16	18.54	57	17289	20274	64461112
Negativism	81.15	18.54	22	17324	738	64480648
Incorrect dose administered	73.30	18.54	86	17260	60679	64420707
Dystonia	71.83	18.54	51	17295	18814	64462572
Depression	71.04	18.54	154	17192	183137	64298249
Paranoia	68.80	18.54	47	17299	16305	64465081
Affect lability	66.39	18.54	37	17309	8953	64472433
Depressed mood	65.00	18.54	67	17279	40945	64440441
Anaemia	64.41	18.54	12	17334	378668	64102718
Product tampering	62.53	18.54	14	17332	207	64481179
Speech disorder	60.82	18.54	70	17276	48371	64433015
Therapeutic response unexpected	60.24	18.54	44	17302	16957	64464429
Product administered to patient of inappropriate age	57.49	18.54	27	17319	4574	64476812
Off label use	56.14	18.54	325	17021	632481	63848905
Decreased appetite	55.54	18.54	184	17162	281105	64200281
Withdrawal syndrome	53.68	18.54	47	17299	23445	64457941
Feeling jittery	53.06	18.54	34	17312	10601	64470785
Mania	52.89	18.54	40	17306	16246	64465140
Dermatillomania	52.71	18.54	12	17334	192	64481194
Therapeutic response shortened	49.47	18.54	32	17314	10138	64471248
Neutropenia	49.43	18.54	4	17342	239620	64241766
Death	49.20	18.54	35	17311	482670	63998716
Mood swings	48.27	18.54	39	17307	17429	64463957
Nervousness	46.31	18.54	48	17298	29508	64451878
Trismus	44.10	18.54	23	17323	4878	64476508
Trichotillomania	43.30	18.54	10	17336	171	64481215
Euphoric mood	42.95	18.54	25	17321	6566	64474820
Pyrexia	41.25	18.54	54	17292	558590	63922796
Sleep disorder	40.62	18.54	64	17282	59645	64421741
Psychotic disorder	40.12	18.54	48	17298	34530	64446856
Somnolence	39.95	18.54	133	17213	203512	64277874
Vision blurred	39.74	18.54	80	17266	90236	64391150
Heart rate increased	39.42	18.54	84	17262	98591	64382795
Emotional disorder	38.82	18.54	30	17316	12577	64468809
Change in sustained attention	38.69	18.54	6	17340	7	64481379
Coordination abnormal	38.40	18.54	32	17314	14932	64466454
Thrombocytopenia	38.21	18.54	7	17339	223794	64257592
Tachyphrenia	36.39	18.54	15	17331	1861	64479525
Oculogyric crisis	35.16	18.54	16	17330	2522	64478864
Unevaluable event	32.80	18.54	53	17293	50436	64430950
Hyperkinesia	31.99	18.54	15	17331	2531	64478855
Intentional overdose	31.89	18.54	73	17273	89871	64391515
Acne	31.77	18.54	35	17311	23046	64458340
Intentional self-injury	31.55	18.54	39	17307	29005	64452381
Palpitations	30.83	18.54	79	17267	104409	64376977
Serotonin syndrome	30.81	18.54	45	17301	39237	64442149
Sepsis	30.32	18.54	12	17334	230329	64251057
Thinking abnormal	30.25	18.54	25	17321	11531	64469855
Headache	30.11	18.54	244	17102	529223	63952163
Initial insomnia	30.05	18.54	19	17327	5785	64475601
Hunger	29.93	18.54	17	17329	4264	64477122
Accidental exposure to product by child	29.26	18.54	14	17332	2471	64478915
Social avoidant behaviour	28.94	18.54	17	17329	4540	64476846
Hypotension	28.93	18.54	36	17310	380938	64100448
Drug diversion	28.73	18.54	11	17335	1125	64480261
Joint swelling	28.71	18.54	11	17335	215371	64266015
Pulmonary embolism	28.68	18.54	3	17343	146353	64335033
Exposure via skin contact	28.35	18.54	7	17339	161	64481225
Hallucination	27.96	18.54	61	17285	72727	64408659
Haemoglobin decreased	27.65	18.54	9	17337	195054	64286332
Hyperhidrosis	27.57	18.54	85	17261	124835	64356551
Diarrhoea	27.50	18.54	101	17245	722603	63758783
Polydipsia psychogenic	26.86	18.54	7	17339	201	64481185
Inability to afford medication	26.48	18.54	12	17334	1874	64479512
Tardive dyskinesia	26.44	18.54	21	17325	9157	64472229
General physical health deterioration	26.33	18.54	11	17335	204414	64276972
Stress cardiomyopathy	26.28	18.54	21	17325	9236	64472150
Atrial fibrillation	25.88	18.54	7	17339	171082	64310304
Arthralgia	25.75	18.54	50	17296	442210	64039176
Streptococcal infection	25.69	18.54	19	17327	7460	64473926
Platelet count decreased	25.10	18.54	7	17339	167704	64313682
Tremor	24.88	18.54	92	17254	148138	64333248
Restlessness	24.80	18.54	41	17305	39744	64441642
Cardiac failure congestive	24.77	18.54	3	17343	130577	64350809
Renal failure	24.68	18.54	9	17337	181679	64299707
Screaming	24.63	18.54	14	17332	3515	64477871
Panic attack	24.16	18.54	29	17317	20924	64460462
Adverse event	23.69	18.54	40	17306	39449	64441937
Rabbit syndrome	23.30	18.54	7	17339	341	64481045
Product prescribing error	22.87	18.54	37	17309	35232	64446154
Dyspnoea	22.63	18.54	108	17238	718566	63762820
Increased appetite	22.58	18.54	20	17326	10126	64471260
Mydriasis	22.43	18.54	24	17322	15288	64466098
Urinary tract infection	22.00	18.54	18	17328	231578	64249808
Tachycardia	21.97	18.54	89	17257	149490	64331896
Respiratory failure	21.87	18.54	8	17338	161175	64320211
Amphetamines negative	21.66	18.54	3	17343	0	64481386
Poor quality sleep	21.48	18.54	26	17320	18925	64462461
Amphetamines positive	21.23	18.54	6	17340	235	64481151
Affective disorder	21.01	18.54	16	17330	6564	64474822
Cardiac failure	20.81	18.54	5	17341	132368	64349018
Malignant neoplasm progression	20.43	18.54	3	17343	112868	64368518
Oedema peripheral	20.41	18.54	16	17330	210301	64271085
Drug dependence	20.32	18.54	34	17312	33278	64448108
Fall	20.26	18.54	52	17294	416774	64064612
Stress	20.21	18.54	48	17298	60486	64420900
Product use issue	19.74	18.54	87	17259	151628	64329758
Myocardial infarction	19.68	18.54	10	17336	165811	64315575
Infusion related reaction	19.40	18.54	10	17336	164457	64316929
Abnormal loss of weight	19.35	18.54	16	17330	7384	64474002
Performance status decreased	19.26	18.54	14	17332	5350	64476036
Hypoaesthesia	19.04	18.54	81	17265	139027	64342359
Apathy	18.97	18.54	19	17327	11213	64470173
Gastrointestinal haemorrhage	18.93	18.54	6	17340	132306	64349080
Memory impairment	18.62	18.54	58	17288	85624	64395762

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06BA12	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D000697	Central Nervous System Stimulants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
FDA PE	N0000175729	Central Nervous System Stimulation
FDA EPC	N0000175739	Central Nervous System Stimulant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Attention deficit hyperactivity disorder	indication	406506008
Binge eating disorder	indication	439960005
Narcolepsy	off-label use	60380001	DOID:8986
Gilles de la Tourette's syndrome	contraindication	5158005	DOID:11119
Bipolar disorder	contraindication	13746004	DOID:3312
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Feeling agitated	contraindication	24199005
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Aggressive behavior	contraindication	61372001
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Arteriosclerotic vascular disease	contraindication	72092001
Cardiomyopathy	contraindication	85898001	DOID:0050700
Weight loss	contraindication	89362005
Structural disorder of heart	contraindication	128599005
Seizure disorder	contraindication	128613002
Motor tic disorder	contraindication	230337001
Cerebrovascular accident	contraindication	230690007
Mania	contraindication	231494001
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Myocardial infarction in recovery phase	contraindication	418044006
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.84	acidic
pKa2	10.65	Basic
pKa3	7.51	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	RELEASING AGENT	CHEMBL	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	RELEASING AGENT	DRUGBANK	CHEMBL
Synaptic vesicular amine transporter	Transporter	Q05940	VMAT2_HUMAN	INHIBITOR	CHEMBL	CHEMBL

External reference:

ID	Source
4026030	VUID
N0000176089	NUI
D04747	KEGG_DRUG
608137-33-3	SECONDARY_CAS_RN
4026030	VANDF
4026031	VANDF
C1873633	UMLSCUI
CHEBI:135925	CHEBI
CHEMBL1201222	ChEMBL_ID
CHEMBL1201178	ChEMBL_ID
D000069478	MESH_DESCRIPTOR_UI
DB01255	DRUGBANK_ID
7213	IUPHAR_LIGAND_ID
8690	INN_ID
H645GUL8KJ	UNII
11597698	PUBCHEM_CID
673579	RXNORM
108098	MMSL
23471	MMSL
d06663	MMSL
011972	NDDF
011987	NDDF
425597005	SNOMEDCT_US
426249000	SNOMEDCT_US
427427002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3655	CAPSULE	70 mg	ORAL	NDA	33 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5827	CAPSULE	50 mg	ORAL	NDA	33 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5916	CAPSULE	30 mg	ORAL	NDA	33 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6009	CAPSULE	40 mg	ORAL	NDA	33 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-101	CAPSULE	10 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-101	CAPSULE	10 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-102	CAPSULE	20 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-102	CAPSULE	20 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-103	CAPSULE	30 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-103	CAPSULE	30 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-104	CAPSULE	40 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-104	CAPSULE	40 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-105	CAPSULE	50 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-105	CAPSULE	50 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-106	CAPSULE	60 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-106	CAPSULE	60 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-107	CAPSULE	70 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-107	CAPSULE	70 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-115	TABLET, CHEWABLE	10 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-115	TABLET, CHEWABLE	10 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-116	TABLET, CHEWABLE	20 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-116	TABLET, CHEWABLE	20 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-117	TABLET, CHEWABLE	30 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-117	TABLET, CHEWABLE	30 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-118	TABLET, CHEWABLE	40 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-118	TABLET, CHEWABLE	40 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-119	TABLET, CHEWABLE	50 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-119	TABLET, CHEWABLE	50 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-120	TABLET, CHEWABLE	60 mg	ORAL	NDA	37 sections
Vyvanse	HUMAN PRESCRIPTION DRUG LABEL	1	59417-120	TABLET, CHEWABLE	60 mg	ORAL	NDA	37 sections